AstraZeneca PLC a biopharmaceutical company focuses on the discovery development manufacture and commercialization of prescription medicines. The company offers Imjudo Datroway Iressa Tagrisso Imfinzi Lynparza Calquence Enhertu Orpathys Truqap Zoladex Faslodex Farxiga Brilinta Crestor Seloken Lokelma Roxadustat Andexxa Wainua Symbicort Fasenra Pulmicort Breztri/Trixeo Saphnelo Tezspire Airsupra Ultomiris Soliris Strensiq Koselugo Kanuma Atacand Plendil Modip Splendil Munobal Flodil Komboglyze Qtern Byetta XIGDUO Accolate Accoleit Vanticon Beyfortus Synagis FluMist tixagevimab and cilgavimab and sipavibart. It also provides Bricanyl Respules Eklira Genuair/Tudorza/Bretaris Bricanyl Turbuhaler Rhinocort Bevespi Aerosphere Daliresp/Daxas Oxis Turbuhaler Breztri Aerosphere Duaklir Genuair Kavigale Evusheld Fluenz/FluMist and Voydeya. The company offers its products for ocology cardiovascular renal and metabolism respiratory & immunology vaccines and immune and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom the United States Europe and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare life sciences and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates with the potential to treat diseases across multiple indications; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge the United Kingdom.